ABSTRACT A high performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) method was developed to measure the thymosin alpha 1 (Tα1) concentration in human serum. T α1 in human serum was determined by solid phase extraction and reverse phase LC-MS/MS.
INTRODUCTION
Thymosin alpha 1 (Tα1) is a peptide that has been evaluated for its immunomodulatory activities and therapeutic potential in several diseases, including chronic hepatitis B [1] [2] [3] and C [4] [5] [6] , acquired immunodeficiency syndrome (AIDS) [ 7, 8] , depressed response to vaccination [9] [10] [11] , and cancer [12, 13] . The basis for T α1 effectiveness in these conditions may be through modulation of immunological responsiveness, as T α1 has been shown to have effects on immune modulators and to increase T-cell differentiation and maturation. Tα1 has been shown to increase production of IFNγ[interferon gamma? Per AMA the abbreviation for interferon is INF.], interleukin 2 (IL-2), IL-3, and expression of IL-2 receptor following activation by mitogens or antigens [ 1, 14, 15] . This pattern of enhanced cytokine production (ie, IFNγ and IL-2) suggests that Tα1 favors progression to a type 1 T helper cells (Th1) type of immune response. T α1 has also been shown to increase natural killer (NK)-cell activity [16, 17] and increase antibody response to T-cell-dependent antigens [18, 19] . Recently, Tα1 was shown to antagonize dexamethasone-induced apoptosis in thymocytes in vitro in a dosedependent fashion [ 20] . T α1 stimulates thymopoiesis in a human coculture system by increasing the number of thymocytes and expanding CD44+25+3-and CD3+CD4+ T cells [21] .
Tα1 is a 28− amino acid peptide with an acetylated N-terminus. It was first isolated from a preparation of bovine thymus, called thymosin fraction 5, by CM-and DEAE-cellulose chromatography and 3-column gel filtration steps [ 22, 23] . Partial sequencing of T α1 isolated from human-derived thymosin fraction 5 did not reveal any structural differences from the bovine peptide [24] , suggesting the conservation of the sequence of this peptide in mammals. Tα1 has also been synthesized by solidphase peptide synthesis; this is the material that has been used in recent clinical trials.
Endogenous Tα1 can be detected in serum, where levels measured in more than 600 healthy adults by enzyme-linked immunosorbent assays (ELISA) were found to be in the 0.1 to 1 ng/ml range [24] [25] [26] [27] . The circulating concentration of Tα1 tends to be lower in diseased individuals and higher during pregnancy [28] [29] [30] . The source and mechanisms of release and regulation of circulating T α1 are unknown. T α1 is contained in the sequence of prothymosin, a 126− amino acid peptide that is reported to be found in the cell nucleus and has been examined in terms of its potential effects on cell proliferation. T α1 is found in highest concentrations in the thymus but has also been found in spleen, lung, kidney, brain, blood, and a number of other tissues.
Although circulating concentrations of T α1 have been measured by ELISA and radioimmunoassay (RIA), these methods have prolonged sample preparation time or have not been very sensitive or specific.
The study presented here describes a fast and reproducible LC-MS/MS method to determine concentrations of Tα1 in human serum between 0.5 ng/ mL and 100 ng/ mL, the concentrations seen in both healthy subjects and in patients after pharmacologic administration. The method employs a simple reverse-phase SPE extraction combined with LC-MS/MS multiple reaction monitor (MRM) detection.This method is accurate and precise, as well as sensitive, with only 30 µ L required for injection. The run time is only 8 minutes, so the method can be used in both clinical trial samples as well as for pharmacokinetic studies [31] . 
MATERIALS AND METHODS

Materials
Sample Preparation
Standard Preparation: An accurately weighed amount of Tα1 was dissolved in water to produce 100 µ g/mL stock solution. ( Tα 1 is stable in water.)
Further dilutions were made to produce a series of Tα1 working stock solutions. A 100 µ g/mL stock internal standard solution was also made in water. A 600 ng/ mL internal standard working stock solution was further diluted from this stock solution. New dilutions were made when needed. All solutions were stored at − 20° C. All working stock solutions were thawed and vortexed at room temperature before use.
Serum Extraction: Human serum samples were spiked with 50 µ L of different concentrations of Tα1 working stock solutions and 50 µ L of 600 ng/mL internal standard working stock solution to achieve different drug serum concentrations. Human serum control blank samples were spiked with 50 µ L water and the same amount of internal standard working stock solution. Tα1 calibration curve standards (0.5, 1, 5, 20, 30, 50, 90, and 100 ng/ mL) were prepared by spiking appropriate Tα1 working stock solutions (10, 20, 100, 200, 400, 1000, 1800, and 2000 ng/ mL) and internal standard working stock solution into 1000 µ L of human serum. Quality control (QC) samples (1, 2800.00 (NEB) Nebulizer Gas (N2):
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20, 70, 90 ng/mL) were prepared by using another set of 40, 100, 200, 400, 1400, and 1800 ng/mL T α1 working stock solutions. Acetic acid solution was added to the sample and shaken violently. Ethanol, water, and acetic acid solutions were used to pretreat Supelclean™ LC-18 SPE Tubes (6 mL) ( Supelco, Bellefonte, PA). The samples were loaded on to the SPE cartridges and washed with 3-mL acetic acid solution and 10 mL water. The analyte and internal standard were eluted with 6 mL 4% acetic acid in 86% ethanol. The eluant was collected and dried under N 2 in a 37° C water bath. Samples were reconstituted with 1000 µ L 5 mM NH 4 OAc solution (pH=7.2 by NH 4 OH). They were then centrifuged and transferred to HPLC vials for analysis.
HPLC Conditions
The HPLC system consisted of 2 Shimadzu (Shimadzu Scientific Instruments, Inc., Columbia, MD) LC10ATvp binary pumps, an SIL-10ADvp auto injector, and an SCL-10Avp system controller. This system is capable of delivering a 2-solvent gradient. A UV detector (Shimadzu SPD-10AVvp) was also online but was not used. The mobile phases were (1) 5 mM NH 4 OAc with 0.1% formic acid (vol/ vol) and (2) 5 mM NH 4 OAc acetonitrile/H 2 O (90/10, vol/vol) solution with 0.1% formic acid (vol/vol). A 30-µ L sample was injected by the Shimadzu auto injector. The analytical column used was a Phenomenex (Torrance, CA) Columbus 2 × 50-mm C18 column. The particle size was 5 µ m, and the flow rate was 0.3 mL per minute. The total chromatography time was 8 minutes. Retention times were determined by injecting a standard solution into the HPLC system for analyte and internal standard respectively.
MS Conditions
The mass spectrometer was a PE Sciex API-365 LC/MS/MS system. The Turbo ionspray interface was used. Turbo ionspray gas was set at 8 L per minute at 25 psi. The instrument was calibrated before sample analysis. Preliminary Q1 scan and product ion scan of analyte, Tα1, and internal standard were carried out. The specific precursor ions and product ions were chosen based on these results. Instrument optimization was performed to achieve more sensitive detection based on these ion pairs. Serum samples were analyzed and T α1 was quantitated by the MRM mode. An example of detailed instrumental parameters is listed in Table 1 . This method employs highly specific LC-MS/MS for the detection mode, coupled with the characteristic retention time observed for the analyte on the appropriate HPLC column. Therefore no further confirmation is required. 
RESULTS AND DISCUSSION
Q1 AND PRODUCT ION SCAN RESULTS
The molecular weight of Tα1 is 3108 Da. Its single charged molecular ion could not be observed by the LC-MS/MS instrument because it is above the instrument's mass detection range. A preliminary Q1 scan study of T α1 demonstrated that under experimental conditions T α1 forms a triple-charged species (M+3H) 3+ at Q1, whose m/z ratio is 1037 (Figure 1 ). The double-charged molecular ion (m/z=1555, (M+2H) 2+ ) and quadruple-charged molecular ion (m/z=778, (M+4H) 4+ ) were also observed in other experiments with much lower intensity. Other experiments showed that a lower pH value, eg, having more formic acid in the mobile phase, favors higher charged species. Using the triple-charged ion (m/z = 1037) as the precursor ion in the product ion scan mode produced m/z = 316 and 387 as major fragments, along with a few other fragments (Figure 2) . Ion 316 was assigned to Ala-Glu-Asn from the Tα1 C terminus and ion 387 was assigned to T α1's acetylated N-terminus (Ac-Ser-Asp-Ala-Ala). Some other fragments were also assigned: the 244 ion was assigned to Glu-Asn and the 227 ion was assigned to (Ac-Ser-Asp)-H 2 O.
The precursor molecular ion with m/z 1037 and the product ion with m/z 316 were chosen to represent Tα1 in the MRM experiment. Internal standard endorphin Ac (1-26) was also tested under Q1 and MS/MS mode. Molecular ion and product ion pair for the internal standard (968.2→ 320) MRM mode detection were also chosen based on the Q1 and MS/MS experimental results. The Q1 scan of endorphin Ac (1-26) showed a triple-charged ion [M+3H] +3 with m/z 968.2. The product ion scan of the m/z 968.2 precursor gave a dominant product ion with m/z 320, which could be assigned to (Ac-TyrGly-Gly), a fragment from the endorphin N terminus.
HPLC Retention
Tα1 and the internal standard endorphin Ac (1-26) solvent standard solutions were injected separately to obtain their retention times. MRM detection was used in the experiments. A matrix standard, which contained both Tα1 and internal standard endorphin, was tested under the same conditions to reveal matrix effects and possible interferences. A typical matrix standard chromatogram is shown in Figure 3 . No interference was observed in the analyte or internal standard retention windows. Their retention times were 3.8 minutes and 5.9 minutes, respectively.
Linearity, Limit of Detection (LOD), and Limit of Quantitation (LOQ)
Three sets of 8 human serum standard curve samples, 6 levels of QC samples using different working stock 
Calibration Standards Statistical Results
Drug Serum Concentration (ng/mL) solutions, and 2 serum blank samples were prepared as described above. The calibration standards ranged from 0.5 ng/ mL to 100 ng/ mL (0.5, 1, 5, 20, 30, 50, 90, and 100 ng/ mL). Each standard was injected at least once in the sample set. All data points acquired on the same day were collected to construct the calibration curve. Linearity was obtained by fitting all data points with weighted linear regression (1/concentration) using analyte and internal standard peak areas. All 3 sets were analyzed on 3 consecutive days. Results are summarized in 
Accuracy, Precision, Stability, and Specificity
Six levels of QC samples were analyzed in each sample set, as well as a mobile phase blank and 2 human serum controls. No detectable levels of Tα1 were observed in the mobile phase blank or control serum blanks.
All QC samples were also analyzed on 3 consecutive days. The results are summarized in Table 3 . CV% and RE% statistical calculations show that they are all < 15%. Thus, this method is accurate and precise in the calibration range.
Stability tests were also performed. Bench top (12 hours) and − 20° C freezer storage samples (3 months) as well as 3 cycles of freeze/thaw at -20° C were tested. No degradation was observed for Tα1 or internal standard in serum. The analytes were stable under the above analytical conditions.
A carryover problem was observed for the higher concentration sample of Tα1 on the auto injector. Appropriate methods should be used for eliminating the carryover problem in order to detect a low level of Tα1. In our case, 500 µ L of rinse solution on the Shimadzu SIL-10ADvp Auto injector was used. After each injection, this pretreatment with a large volume rinse involved several rinse steps, and eliminated the carryover problem.
CONCLUSIONS
This LC-MS/MS method demonstrates high accuracy and precision for analysis of Tα1 in a human serum matrix. Tα1 was extracted from serum by reverse phase SPE extraction and analyzed on a reverse phase LC-MS/MS instrument. In these experiments, the sample preparation time for 1 person to process all 46 samples (3 sets of 8 standards, 5 LLOQ samples, 2 serum controls, and 3 levels of QC samples in 5 replicates) was 6 hours. The HPLC and MS/MS acquisition time was 8 minutes. This analytical method is thus quick, reliable, and accurate for determination of Tα1 in serum matrix. This could prove to be useful for analysis of clinical trial samples and for pharmacokinetic studies. 
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